Naveris Acquired by CareDx | Healthcare M&A Deal

CareDx has acquired Naveris, a diagnostics imaging business in the U.S., for $160M. CareDx acquisitions expand into precision oncology blood-based monitoring, with Naveris specializing in HPV-driven cancer molecular residual disease (MRD) surveillance using TTMV DNA. Naveris’ NavDx liquid biopsy test detects and tracks viral DNA fragments to support non-invasive patient management across head and neck and anal cancer pathways. The strategic acquisition is structured as a platform acquisition with $160M up-front cash plus up to $100M in revenue-based milestones, and it is expected to close in Q3 2026 under customary conditions.